Qingrou Li

Title: Innovations of Qingrou Li in Antibody Development

Introduction

Qingrou Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer treatment. With a total of 4 patents, his work focuses on innovative solutions to combat diseases related to HER2 overexpression.

Latest Patents

One of his latest patents is titled "Antibody binding to human HER2 and preparation method and use thereof." This invention provides an antibody that specifically binds to human HER2, demonstrating improved biological activity in inhibiting the proliferation of tumor cells compared to existing treatments like Perjeta. The antibody has a unique antigen-binding epitope, which allows it to be used in drugs aimed at treating HER2-related cancers, showcasing promising clinical applications.

Another notable patent is the "Tissue factor-targeted antibody-drug conjugate." This invention involves an antibody-drug conjugate (ADC) that binds to the tissue factor antigen with high specificity. The ADC exhibits high affinity, low immunogenicity, and significant anti-tumor activity, making it a valuable tool in cancer therapy.

Career Highlights

Qingrou Li has worked at esteemed institutions such as Fudan University and Shanghai Miracogen Inc. His experience in these organizations has allowed him to advance his research and contribute to the development of innovative therapeutic solutions.

Collaborations

Throughout his career, Qingrou Li has collaborated with notable colleagues, including Xuesai Zhang and Ke Yu. These partnerships have fostered a collaborative environment that enhances the research and development of new biotechnological advancements.

Conclusion

Qingrou Li's contributions to antibody development represent a significant advancement in cancer treatment. His innovative patents and collaborations highlight his commitment to improving therapeutic options for patients.